| Application | Recommended Dilution |
|---|---|
| WB | 1:500-1:2000 |
| IHC | 1:50-1:200 |
| FC | 1:50-1:200 |
HSPA5, commonly known as GRP78 or BiP, serves as a master regulator of endoplasmic reticulum homeostasis and the unfolded protein response. This essential chaperone protein plays a critical role in protein folding, ER stress signaling, and cellular adaptation to metabolic challenges. Its elevated expression in cancer cells and involvement in tumor progression, drug resistance, and metastasis has made HSPA5 a compelling target for oncology research and therapeutic development.
This recombinant monoclonal antibody against human HSPA5, clone 9G10, offers the reproducibility and consistency that demanding research applications require. Because recombinant antibodies are produced from defined sequences rather than hybridoma cultures, you can expect reliable performance across experiments and between lots, eliminating a common source of variability in long-term studies.
Validation data demonstrates robust performance across multiple experimental platforms. Western blot analysis confirms specific detection of HSPA5 at the expected 72 kDa molecular weight across a diverse panel of human cell lines, including U-251MG glioblastoma, HepG2 hepatocellular carcinoma, HeLa cervical cancer, Colo205 colorectal adenocarcinoma, A549 lung carcinoma, and PC-3 prostate cancer cells. For tissue-based studies, immunohistochemistry validation in human liver cancer, breast cancer, and kidney tissue sections shows clear staining patterns suitable for pathological investigations. Flow cytometry analysis in U251 cells further extends the antibody's utility to single-cell protein expression studies.
Whether you are investigating ER stress pathways, characterizing tumor microenvironment adaptations, or exploring HSPA5 as a therapeutic target, this antibody provides the experimental flexibility and validated performance to support your research objectives.
Email: support@cusabio.com
Distributors Worldwide